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Vincenzo Berghella, MD; Claudia Caissutti, MD; Gabriele Saccone, MD; Adeeb Khalifeh, MDhere is controversy regarding the diagnosis of gestationalT diabetes mellitus (GDM) by either the One Step or Two
Step approaches. The One Step approach consists of an oral
glucose tolerance test with a 75-g glucose overload with
2 hours duration that measures plasma glucose concentration
at fasting state, 1 hour, and 2 hours after glucose adminis-
tration. A positive result is deﬁned as 1 value higher than 92,
180, or 153 mg/dL, respectively.1e4 The Two Step approach
consists of a nonfasting oral 50-g glucose load, with a glucose
blood measurement 1 hour later. A positive result is deﬁned
as a blood glucose value higher than 130, 135, or 140 mg/dL;
the most common value used is 135 mg/dL.5 A positive
screening test is followed by a diagnostic test that consists of a
100-g oral glucose load with the glucose measurement fasting
and after 1, 2, and 3 hours. A positive result is deﬁned as 2
values higher than target values. Although the American
College of Obstetricians and Gynecologists recommends the
Two Step approach, the International Association of the
Diabetes and Pregnancy Study Groups, American Diabetes
Association, International Federation of Gynecology and
Obstetrics, and World Health Organization recommend the
One Step approach.1e7
There are several ways of comparing these approaches with
GDM testing. First, one should establish whether women who
meet the criteria for GDM based on the One Step test, but not
on the Two Step test, have worse maternal and perinatal
outcomes, in particular, the perinatal morbidity and mortality
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approaches. Third, outcomes could be examined from trials
that randomly assign women to the One Step vs the Two Step
approach. Fourth, outcomes could be examined from ran-
domized controlled trials in which women underwent both
the One Step and the Two Step test, and the women whose
result is positive for the One Step test, but negative for the
Two Step test, could be assigned randomly to treatment of
GDM vs no treatment.
A review that analyzed the evidence from 8 retrospective
studies that included 29,983 women showed that, compared
with women whose result was negative at the One Step test,
women whose result was positive at the One Step test, but
negative at the Two Step test, have higher incidences of
gestational hypertension, preeclampsia, preterm birth, cesar-
ean delivery, macrosomia, large-for-gestational-age (LGA)
infants, neonatal intensive care admission, and hypoglycemia
(Table 1).8 The evidence is clear that a milder degree of
hyperglycemia in pregnancy that is detected by the One Step
test, but not the Two Step, is associated with worse maternal
and perinatal outcomes. In fact, even pregnancies that are
positive at the 50-g 1 hour glucola test, but negative at the
3-hour test of the Two Step approach, have been shown to
be associated with these maternal and perinatal complica-
tions.9 The relationship between hyperglycemia and worse
maternal and perinatal outcomes is on a continuum.1
“Before and after” studies that compared a period when the
Two Step test was used vs another period when the One Step
test was used for GDM testing have provided conﬂicting
results.10,11 Although the most recent study showed increases
in the incidences of GDM (from 6.9% with the Two Step to
11.4% with the One Step), induction (25.2e28.6%) and
neonatal hypoglycemia (1.3e2.0%) associated with the One
Step approach, there were no signiﬁcant decreases but only
trends for less cesarean delivery (18.5e17.0%), macrosomia
(2.5e2.1%), and LGA (10.4e9.5%).10 As the authors state,
several confounding variables in this before and after study
could have affected results. In fact, the One Step period also
saw implementation of hemoglobin A1c testing before 16
weeks, which could also have affected results. Moreover, there
are several management issues that can inﬂuence outcome in
GDM pregnancies (Table 2).12 Non-randomized control trials
do not control for these.
There is a randomized controlled trial in which women
underwent both the One Step and the Two Step test; theMONTH 2019 American Journal of Obstetrics & Gynecology 1
TABLE 1
Complications in pregnancies that are positive at
the One Step test but negative at the Two Step test,
compared with pregnancies that are negative at the
One Step test8
Maternal Neonatal
Gestational hypertension Preterm birth
Preeclampsia Macrosomia
Cesarean delivery Large for gestational age
Intensive care unit admission
Hypoglycemia
Berghella. One Step approach to GDM. Am J Obstet Gynecol 2019.
TABLE 3
Neonatal benefits that were associated
significantly with gestational diabetes mellitus
testing with the use of the One Step test, compared
with the Two Step test, by data from a
metaanalysis of the 4 published randomized
controlled trials18
Variable Decreased by, %
Large for gestational age 57
Hypoglycemia 48
Neonatal intensive care unit admission 51
Berghella. One Step approach to GDM. Am J Obstet Gynecol 2019.
Viewpoint ajog.orgwomen whose result was positive for the One Step, but
negative for the Two Step, test were assigned randomly to
treatment of GDM vs no treatment.13 No maternal or peri-
natal outcomes were reported.
There are 4 randomized controlled trials that compared the
One Step vs the two Step approaches: 2 from United
States,14,15 1 from Canada,16 and 1 from Turkey.17 In these
randomized controlled trials, women were assigned randomly
to be screened for GDM with either the One Step or the Two
Step approach. A metaanalysis of these 4 randomized
controlled trials, which included 2617 women and 152 total
cases of GDM, showed, in a comparison of the One Step
approach with the Two Step approach, that the incidence of
GDM was not signiﬁcantly increased from 4.4e8.3% and that
mothers gained 1.3 kg less weight and had a nonsigniﬁcant
decreases by 34% in preeclampsia and by 17% in cesarean
delivery, respectively.18 The One Step approach was also
associated with several neonatal beneﬁts, which included
signiﬁcantly decreased incidences of LGA infants by 57%,TABLE 2
Selected management issues that can influence
outcome in gestational diabetes mellitus
pregnancies
Indications for screening (who to screen)
Timing of screening (when to screen)
Type of screening (eg, One vs Two Step tests; how to screen)
Criteria for diagnosis
Criteria to start therapy after diet alone
Type of initial therapy (eg, insulin vs oral hypoglycemic agent)
Dose and frequency of initial therapy
Frequency of glucose monitoring
Target glucose values
Criteria for pharmacologic therapy dose adjustment
Criteria for adding or switching pharmacologic therapy
Berghella. One Step approach to GDM. Am J Obstet Gynecol 2019.
2 American Journal of Obstetrics & Gynecology MONTH 2019hypoglycemia by 48%, and neonatal intensive care unit admis-
sionby 51%.Neonatal death occurred in 1 babyof 1mother who
was assigned randomly to the One Step test and in 4 babies of
mothers whowere assigned randomly to the Two Step approach
(a 74% nonsigniﬁcant decrease for the One Step test; Table 3).18
The Two Step test is associated also with a 4.2% chance of not
completing the test (only the 50-g part was done and not the
diagnostic 100-g 3-hour test) and with lower compliance
compared with the One Step test.14 The Two Step test is also
associated with a later gestational age at diagnosis, given that
it comprises of 2 tests, which usually takes approximately
2 weeks for ﬁnal diagnosis compared with the immediate
diagnostic results that are obtained from the One Step test.
The data represent evidence of randomized controlled trial
(level-1) data. Tests of heterogeneity in the metaanalysis and of
quality all point to the better outcomes in the One Step test
group.18 Beneﬁt of the One Step approach does make not
only statistical but also clinical sense in pregnant women.
The decreased incidence in LGA infants may be the most
important beneﬁt of the use of the One Step vs the Two Step
tests for GDM screening. Being LGA at birth is associated
with long-term health harms, such as obesity, diabetes
mellitus, and metabolic syndrome.19
In summary, the One Step approach is associated with an
increase in compliance, earlier diagnosis, and a nonsigniﬁcant
increased incidence of GDM from approximately 4e8% and
is also associated with signiﬁcantly fewer LGA infants,
neonatal hypoglycemia, and admission to the neonatal
intensive care unit, compared with screening with the Two
Step approach, according to the level 1 evidence from 4
randomized controlled trials with 2617 women (Table 3).18
Therefore, it is time to use the One Step approach for diag-
nosing GDM in the United States and to reconsider this
recommendation by the guidelines of the American College
of Obstetricians and Gynecologists. -REFERENCES
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